Total
0
Shares
Elixinol Global (ASX:EXL) - Group CEO, Oliver Horn
Group CEO, Oliver Horn
Source: Cannabiz
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Elixinol Wellness (EXL) is not going ahead with its acquisition of CannaCare Health citing intensified competition in the German cannabidiol market
  • The companies entered a binding agreement in March which was due to be settled on July 5
  • Elixinol Chief Executive Officer Oliver Horn says the additional investment required to achieve profitable growth exceeds the company’s risk appetite
  • The company will not be required to pay the initial €3 million (A$4.7 million) cash consideration acquisition
  • Elixinol Wellness shares are down 11.5 per cent and trading at 11.5 cents

Elixinol Wellness (EXL) will not go ahead with its acquisition of CannaCare Health citing intensified competition in the German cannabidiol market.

Elixinol announced it had entered a binding agreement to acquire the German company through its subsidiary on March 15, in a bid to capitalise on a growing European CBD market.

The acquisition was set to be finalised on July 5 2021 however EXL backed out of the deal after identifying “a changed German market outlook with rapidly intensifying competition”.

Elixinol Chief Executive Officer Oliver Horn commented on the withdrawal.

“CannaCare is a leading brand in the German retail market with a strong distribution footprint and is well-positioned for growth,” he said.

“However, over the recent months the German market has become increasingly competitive, and the additional investment required to achieve profitable growth exceeds our current risk appetite.”

CannaCare shareholders are set to cover a portion of Elixinol Wellness’ costs incurred to date stemming from the proposed acquisition.

Further, Elixinol will not be required to pay the initial €3 million (A$4.7 million) cash consideration for the proposed acquisition and CannaCare’s major shareholder Frank Otto will not join the EXL board.

Elixinol Wellness shares were down 11.5 per cent to trade at 11.5 cents at 12:56 pm AEST.

EXL by the numbers
More From The Market Herald
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).